

**Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response**

Unsun Lee, Ludmila Szabova, Victor J. Collins, Melanie Gordon, Kristine Johnson, Deborah Householder, Stephanie Jorgensen, Lucy Lu, Laura Bassel, Fathi Elloumi, Cody J. Peer, Ariana E. Nelson, Sophia Varriano, Sudhir Varma, Ryan D. Roberts, Zoe Weaver Ohler, William D. Figg, Shyam K. Sharan, Yves Pommier, Christine M. Heske

---

**Supplemental Table S2. Details of tolerability study of 5-day-on/2-day-off/5-day-on schedule.**

Compound	Dose	Route	Schedule	N
LMP400	10 mg/kg	IV	5-day-on/2-day-off/5-day-on	5
	15 mg/kg	IV	5-day-on/2-day-off/5-day-on	5
LMP744	20 mg/kg	IV	5-day-on/2-day-off/5-day-on	5
	25 mg/kg	IV	5-day-on/2-day-off/5-day-on	5
LMP776	10 mg/kg	IV	5-day-on/2-day-off/5-day-on	5
	15 mg/kg	IV	5-day-on/2-day-off/5-day-on	5